Hemorheological methods in drug research

Zsolt Marton, R. Halmosi, Tamas Alexy, B. Horváth, A. Tóth, G. Fehér, Katalin Koltai, Gabor Kesmarky, Tamas Habon, B. Sümegi, K. Hideg, K. Tóth

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Development of new drugs is a sophisticated process that requires several, different methods. In our experiments we have applied two rheological models to study experimental and clinically used drugs. The antioxidant properties of several agents were estimated by erythrocyte filtration technique. The known antioxidant compound vitamin E was used to validate our measurements. An experimental cardioprotective agent, H-2545 provided significant protection against oxidative changes in red blood cell filterability (p <0.001). Although some of the examined, known cardiovascular drugs also showed significant antioxidant effect, they were less efficient than H-2545 and the scavenger effect of this novel agent exceeded the antioxidant properties of vitamin E. Modification of mexiletine with a pyrroline ring improved significantly its antioxidant capacity suggesting this molecular segment to be responsible for the antioxidant effect. In our second model the antiplatelet effect of experimental poly(ADP-ribose) polymerase (PARP) inhibitors was evaluated. Two widely used antiplatelet agents: acetyl salicylic acid and eptifibatide served as controls in the validation of the measurements. PARP inhibitors reduced ADP-induced platelet aggregation in a dose-dependent manner (p <0.05). However, their hindrance on platelet aggregation waned as the concentration of ADP rose. Regarding the platelets' role in the development of ischemic vascular diseases, the antiaggregating property of PARP inhibitors may exert additional beneficial effects on tissue blood supply under conditions of compromised vascular flow.

Original languageEnglish
Pages (from-to)243-252
Number of pages10
JournalClinical Hemorheology and Microcirculation
Volume30
Issue number3-4
Publication statusPublished - 2004

Fingerprint

Antioxidants
Research
Pharmaceutical Preparations
Vitamin E
Platelet Aggregation
Adenosine Diphosphate
Erythrocytes
Mexiletine
Cardiotonic Agents
Cardiovascular Agents
Salicylic Acid
Platelet Aggregation Inhibitors
Vascular Diseases
Blood Vessels
Blood Platelets
Poly(ADP-ribose) Polymerase Inhibitors
H 2545

ASJC Scopus subject areas

  • Hematology
  • Physiology

Cite this

Hemorheological methods in drug research. / Marton, Zsolt; Halmosi, R.; Alexy, Tamas; Horváth, B.; Tóth, A.; Fehér, G.; Koltai, Katalin; Kesmarky, Gabor; Habon, Tamas; Sümegi, B.; Hideg, K.; Tóth, K.

In: Clinical Hemorheology and Microcirculation, Vol. 30, No. 3-4, 2004, p. 243-252.

Research output: Contribution to journalArticle

Marton, Zsolt ; Halmosi, R. ; Alexy, Tamas ; Horváth, B. ; Tóth, A. ; Fehér, G. ; Koltai, Katalin ; Kesmarky, Gabor ; Habon, Tamas ; Sümegi, B. ; Hideg, K. ; Tóth, K. / Hemorheological methods in drug research. In: Clinical Hemorheology and Microcirculation. 2004 ; Vol. 30, No. 3-4. pp. 243-252.
@article{f40258022690424cb3424c1c6689b593,
title = "Hemorheological methods in drug research",
abstract = "Development of new drugs is a sophisticated process that requires several, different methods. In our experiments we have applied two rheological models to study experimental and clinically used drugs. The antioxidant properties of several agents were estimated by erythrocyte filtration technique. The known antioxidant compound vitamin E was used to validate our measurements. An experimental cardioprotective agent, H-2545 provided significant protection against oxidative changes in red blood cell filterability (p <0.001). Although some of the examined, known cardiovascular drugs also showed significant antioxidant effect, they were less efficient than H-2545 and the scavenger effect of this novel agent exceeded the antioxidant properties of vitamin E. Modification of mexiletine with a pyrroline ring improved significantly its antioxidant capacity suggesting this molecular segment to be responsible for the antioxidant effect. In our second model the antiplatelet effect of experimental poly(ADP-ribose) polymerase (PARP) inhibitors was evaluated. Two widely used antiplatelet agents: acetyl salicylic acid and eptifibatide served as controls in the validation of the measurements. PARP inhibitors reduced ADP-induced platelet aggregation in a dose-dependent manner (p <0.05). However, their hindrance on platelet aggregation waned as the concentration of ADP rose. Regarding the platelets' role in the development of ischemic vascular diseases, the antiaggregating property of PARP inhibitors may exert additional beneficial effects on tissue blood supply under conditions of compromised vascular flow.",
author = "Zsolt Marton and R. Halmosi and Tamas Alexy and B. Horv{\'a}th and A. T{\'o}th and G. Feh{\'e}r and Katalin Koltai and Gabor Kesmarky and Tamas Habon and B. S{\"u}megi and K. Hideg and K. T{\'o}th",
year = "2004",
language = "English",
volume = "30",
pages = "243--252",
journal = "Clinical Hemorheology and Microcirculation",
issn = "1386-0291",
publisher = "IOS Press",
number = "3-4",

}

TY - JOUR

T1 - Hemorheological methods in drug research

AU - Marton, Zsolt

AU - Halmosi, R.

AU - Alexy, Tamas

AU - Horváth, B.

AU - Tóth, A.

AU - Fehér, G.

AU - Koltai, Katalin

AU - Kesmarky, Gabor

AU - Habon, Tamas

AU - Sümegi, B.

AU - Hideg, K.

AU - Tóth, K.

PY - 2004

Y1 - 2004

N2 - Development of new drugs is a sophisticated process that requires several, different methods. In our experiments we have applied two rheological models to study experimental and clinically used drugs. The antioxidant properties of several agents were estimated by erythrocyte filtration technique. The known antioxidant compound vitamin E was used to validate our measurements. An experimental cardioprotective agent, H-2545 provided significant protection against oxidative changes in red blood cell filterability (p <0.001). Although some of the examined, known cardiovascular drugs also showed significant antioxidant effect, they were less efficient than H-2545 and the scavenger effect of this novel agent exceeded the antioxidant properties of vitamin E. Modification of mexiletine with a pyrroline ring improved significantly its antioxidant capacity suggesting this molecular segment to be responsible for the antioxidant effect. In our second model the antiplatelet effect of experimental poly(ADP-ribose) polymerase (PARP) inhibitors was evaluated. Two widely used antiplatelet agents: acetyl salicylic acid and eptifibatide served as controls in the validation of the measurements. PARP inhibitors reduced ADP-induced platelet aggregation in a dose-dependent manner (p <0.05). However, their hindrance on platelet aggregation waned as the concentration of ADP rose. Regarding the platelets' role in the development of ischemic vascular diseases, the antiaggregating property of PARP inhibitors may exert additional beneficial effects on tissue blood supply under conditions of compromised vascular flow.

AB - Development of new drugs is a sophisticated process that requires several, different methods. In our experiments we have applied two rheological models to study experimental and clinically used drugs. The antioxidant properties of several agents were estimated by erythrocyte filtration technique. The known antioxidant compound vitamin E was used to validate our measurements. An experimental cardioprotective agent, H-2545 provided significant protection against oxidative changes in red blood cell filterability (p <0.001). Although some of the examined, known cardiovascular drugs also showed significant antioxidant effect, they were less efficient than H-2545 and the scavenger effect of this novel agent exceeded the antioxidant properties of vitamin E. Modification of mexiletine with a pyrroline ring improved significantly its antioxidant capacity suggesting this molecular segment to be responsible for the antioxidant effect. In our second model the antiplatelet effect of experimental poly(ADP-ribose) polymerase (PARP) inhibitors was evaluated. Two widely used antiplatelet agents: acetyl salicylic acid and eptifibatide served as controls in the validation of the measurements. PARP inhibitors reduced ADP-induced platelet aggregation in a dose-dependent manner (p <0.05). However, their hindrance on platelet aggregation waned as the concentration of ADP rose. Regarding the platelets' role in the development of ischemic vascular diseases, the antiaggregating property of PARP inhibitors may exert additional beneficial effects on tissue blood supply under conditions of compromised vascular flow.

UR - http://www.scopus.com/inward/record.url?scp=3242740890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3242740890&partnerID=8YFLogxK

M3 - Article

VL - 30

SP - 243

EP - 252

JO - Clinical Hemorheology and Microcirculation

JF - Clinical Hemorheology and Microcirculation

SN - 1386-0291

IS - 3-4

ER -